GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suven Life Sciences Ltd (NSE:SUVEN) » Definitions » Quick Ratio

Suven Life Sciences (NSE:SUVEN) Quick Ratio : 0.00 (As of Dec. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Suven Life Sciences Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Suven Life Sciences's quick ratio for the quarter that ended in Dec. 2024 was 0.00.

Suven Life Sciences has a quick ratio of 0.00. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Suven Life Sciences's Quick Ratio or its related term are showing as below:

NSE:SUVEN' s Quick Ratio Range Over the Past 10 Years
Min: 1.32   Med: 3.63   Max: 22.61
Current: 10.36

During the past 13 years, Suven Life Sciences's highest Quick Ratio was 22.61. The lowest was 1.32. And the median was 3.63.

NSE:SUVEN's Quick Ratio is ranked better than
95.58% of 1017 companies
in the Drug Manufacturers industry
Industry Median: 1.4 vs NSE:SUVEN: 10.36

Suven Life Sciences Quick Ratio Historical Data

The historical data trend for Suven Life Sciences's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suven Life Sciences Quick Ratio Chart

Suven Life Sciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.49 6.45 8.01 22.61 18.94

Suven Life Sciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 18.94 - 10.36 -

Competitive Comparison of Suven Life Sciences's Quick Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Suven Life Sciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suven Life Sciences's Quick Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Suven Life Sciences's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Suven Life Sciences's Quick Ratio falls into.


;
;

Suven Life Sciences Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Suven Life Sciences's Quick Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Quick Ratio (A: Mar. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(2566.735-7.085)/135.161
=18.94

Suven Life Sciences's Quick Ratio for the quarter that ended in Dec. 2024 is calculated as

Quick Ratio (Q: Dec. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0-0)/0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Suven Life Sciences  (NSE:SUVEN) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Suven Life Sciences Quick Ratio Related Terms

Thank you for viewing the detailed overview of Suven Life Sciences's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Suven Life Sciences Business Description

Traded in Other Exchanges
Address
Avenue 7, Road No. 5, Banjara Hills, Number 8-2-334, 6th Floor, SDE Serene Chambers, Hyderabad, TG, IND, 500 034
Suven Life Sciences Ltd is an India-based biopharmaceutical company. The company is focused on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The company's only segment is providing Research and Development services. The company's geographical segment includes India; the USA; Europe and Others. The company generates maximum revenue from the USA. The company earns revenue from the sale of New Chemical Entity (NCE) based Intermediates for CNS disorders.

Suven Life Sciences Headlines

No Headlines